Setting the Record Straight on FDA Approvals in Oncology-Reply

Affiliations

Comment

Diana Zuckerman. JAMA Intern Med. 2017.

. 2017 Aug 1;177(8):1222-1223.

doi: 10.1001/jamainternmed.2017.2251.

No abstract available

Comment in

Setting the Record Straight on FDA Approvals in Oncology-Reply.
Bauer SR, Redberg RF. Bauer SR, et al. JAMA Intern Med. 2017 Aug 1;177(8):1223. doi: 10.1001/jamainternmed.2017.2254. JAMA Intern Med. 2017. PMID: 28783834 No abstract available.

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints.
Rupp T, Zuckerman D. Rupp T, et al. JAMA Intern Med. 2017 Feb 1;177(2):276-277. doi: 10.1001/jamainternmed.2016.7761. JAMA Intern Med. 2017. PMID: 27898978 No abstract available.
Setting the Record Straight on FDA Approvals in Oncology.
Blumenthal G, Kim G, Pazdur R. Blumenthal G, et al. JAMA Intern Med. 2017 Aug 1;177(8):1222. doi: 10.1001/jamainternmed.2017.2241. JAMA Intern Med. 2017. PMID: 28783827 No abstract available.